TGIF2-Induced Hepatic Reprogramming for Diabetes Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, such as islet transplantation, face challenges including inadequate means for preventing rejection and limited islet supply, and existing approaches for reprogramming non-pancreatic cells into pancreatic cells are inefficient due to lineage restrictions and antagonistic factors.
Innovation Solution
Genetically modified human pancreatic progenitor cells expressing TGIF2 are used for reprogramming liver cells into pancreatic cells, enabling effective differentiation into endocrine Beta-cell lineage, thereby addressing the limitations of islet transplantation and lineage reprogramming.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If islet transplantation is performed to treat diabetes, then insulin production and blood sugar regulation are improved, but transplant rejection occurs requiring immunosuppressant drugs with detrimental side effects
Solution Approach 1:
The patent uses viral vectors (AAV8, lentivirus) as intermediaries to deliver TGIF2 gene into liver cells, enabling reprogramming without direct islet transplantation. This intermediary approach avoids immune rejection while achieving the therapeutic effect of insulin production through differentiated beta cells
Solution Approach 2:
Instead of transplanting pancreatic islets directly (conventional approach), the patent inverts the strategy by reprogramming liver cells into pancreatic progenitor cells that then differentiate into beta cells. This reverse approach uses the liver as a source rather than a target, avoiding rejection issues while achieving insulin production
2Adaptability or versatility
If lineage re-programming of non-pancreatic cells into pancreatic cells is attempted, then novel sources of therapeutic cells are provided, but lineage restrictions and antagonistic factors result in inefficient conversion
Solution Approach 1:
The patent changes the molecular parameters by introducing TGIF2 gene expression to alter the transcriptional program of liver cells. This parameter change (gene expression profile) drives the phenotypic conversion from hepatic to pancreatic progenitor state, overcoming lineage restrictions and achieving efficient reprogramming
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver TGIF2 into liver cells, enabling efficient gene transfer and expression. This intermediary system overcomes the barriers of direct cellular reprogramming and achieves high efficiency in converting liver cells to pancreatic progenitor cells
3Manufacturing precision
If Pdx1 expression is used for hepatic to pancreatic re-programming, then some pancreatic differentiation is achieved, but incomplete phenotypic conversion occurs resulting in hybrid phenotypes
Solution Approach 1:
The patent extracts the key reprogramming determinant TGIF2 and uses it to drive complete phenotypic conversion. By focusing on this single critical factor rather than multiple factors including Pdx1, the patent achieves pure pancreatic progenitor phenotypes without hybrid characteristics
Solution Approach 2:
The patent changes the transcriptional parameters by introducing TGIF2 expression, which activates a comprehensive pancreatic gene program. This parameter change drives complete phenotypic conversion to pancreatic progenitor cells, eliminating hybrid phenotypes and achieving pure cell identity
Data Source
Figure 1a~1b
Figure 1c~1e
Figure 2a~2c
AI summary
The invention relates to genetically modified human pancreatic progenitor cells, comprising an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes, in addition to methods for the production of said cells. The invention also comprises an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.